CCHIT launches long-term, post-acute care EHR certs

Jeff Byers | | Health Exec | Informatics
The Certification Commission for Health Information Technology (CCHIT) has announced the first group of EHRs to be certified under the CCHIT Certified 2011 program for Long Term and Post Acute Care (LTPAC), which includes EHR use in care settings such as skilled nursing facilities, home healthcare, hospice and rehabilitation centers.

Products that have been certified under the CCHIT Certified 2011 LTPAC program including additional certification in skilled nursing facility and home health are:
  • AOD Software in Fort Lauderdale, Fla., Answers EHR, version Autumn; and
  • HealthMEDX, Vision in Ozark, Mo., HealthMEDX Vision, version 7.1.10.

LTPAC EHRs may also be certified in the federal Office of the National Coordinator authorized EHR certification program for eligible providers and hospitals if they meet those criteria, the Chicago-based CCHIT added.

Jeff Byers

Related Content

Alabama security breach exposes personal information of cardiologists, heart patients
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions
Best in KLAS 2024 rankings released, showcasing medical imaging IT systems
Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.